Tyruko

Description

Tyruko® is biosimilar to Tysabri®. It is a laboratory-produced monoclonal antibody. It is designed to hamper movement of potentially damaging immune cells from the bloodstream, across the “blood-brain barrier” into the brain and spinal cord.

Tyruko is approved by the U.S. Food and Drug Administration (FDA) as a monotherapy (not to be used in combination with other disease-modifying therapies) for the treatment of relapsing forms of multiple sclerosis, which include clinically isolated syndrome, relapsing-remitting disease (RRMS) and active secondary progressive disease (SPMS with relapses).

Support

Financial Assistance Program

Infusion Center Resources

Infusion Access Foundation – non-profit advocacy organization that helps patients have greater access to infusion therapies. Visit the site to:

Find an infusion center near you
View the Multiple Sclerosis Infusion Guide

Featured Links: >